Exploring the Purdue Pharma Settlement and the Opioid Epidemic

Abstract

Article| March 2021 Exploring the Purdue Pharma Settlement and the Opioid Epidemic Gordon Glantz Gordon Glantz Search for other works by this author on: This Site PubMed Google Scholar ASA Monitor March 2021, Vol. 85, 1–8. https://doi.org/10.1097/01.ASM.0000737016.86682.c0 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation Gordon Glantz; Exploring the Purdue Pharma Settlement and the Opioid Epidemic. ASA Monitor 2021; 85:1–8 doi: https://doi.org/10.1097/01.ASM.0000737016.86682.c0 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search nav search search input Search input auto suggest search filter All ContentAll PublicationsASA Monitor Search Advanced Search Topics: opioid epidemic, opioids With lawsuits piling up against drug companies believed complicit in the opioid crisis, a major precedent was set in November 2020 when Purdue Pharma was ordered to pay an $8.3 billion settlement. The order from Judge Robert Drain, who described the ruling as a “critical building block” to resolve mounting lawsuits against the company, capped off a federal investigation of programs that offered incentives to physicians and an electronic health records company for driving opioid prescriptions. Purdue Pharma – owned by the Sackler family since 1952 (when it was known as Purdue-Frederick) – agreed to plead guilty to three felony criminal counts of wrongdoing. According to The Washington Post, Purdue – with headquarters in Stamford, Connecticut – has earned more than $30 billion since the opioid OxyContin arrived on the market in 1996. Moreover, according to reports, a congressional... © 2021 American Society of Anesthesiologists (ASA), All Rights Reserved.2021 You do not currently have access to this content.